Iodine Deficiency Drug Market by Distribution Channel (Hospital Pharmacies, Drug stores and Retail Pharmacies and Online Providers), Dosage Form (Tablets and Others) and Geography (North America, Europe, APAC and RoW)-Forecast up to 2027
Iodine Deficiency Disorder (IDD) is one of the major worldwide public health issues. An insufficient dietary intake of iodine results in insufficient production of thyroid hormones. Tissues are negatively affected due to insufficient hormone production, which leads to the disease states referred collectively as iodine deficiency disorders, or IDD. Extreme and prolonged iodine deficiency may result in a deficient supply of thyroid hormones. This condition is known as hypothyroidism. IDD is a rare endocrinology illness in which the thyroid gland in the neck produces insufficient amounts or is incapable of creating thyroid hormone owing to a lack of iodine, which is a vital nutrient for the growth and function of the thyroid gland. The body's metabolism, temperature, and heart rate regulation is the responsible of the thyroid hormone. As per the World Health Organization (WHO), approximately 2 billion people around the world are at risk of iodine deficiency, and it is projected that iodine deficiency impacts around 30% of the world population. This rising prevalence is augmenting the demand for iodine deficiency drugs eventually, market growth. Moreover, iodine deficiency causes several issues, ranging from miscarriage and stillbirth to physical and mental retardation and hearing. On the other hand, the adverse impacts associated with levothyroxine drug used for hypothyroidism may limit the market growth. The Iodine Deficiency Drug Market is estimated to grow at a rate of 5.6% CAGR by 2027.
Iodine Deficiency Drug Market on the basis of Distribution Channel
Hospital Pharmacies
Drug stores and Retail Pharmacies
Online Providers
Iodine Deficiency Drug Market on the basis of Dosage Form
Tablets
Others
Iodine Deficiency Drug Market on the basis of Geography
North America
Europe
Asia Pacific
Rest of the World
In the market for Distribution Channel, the market is bifurcated into Hospital Pharmacies, Drug stores and Retail Pharmacies and Online Providers. The Drug stores and Retail Pharmacies segment is likely to dominate the Iodine Deficiency Drug market growth. This is due to the surge in demand for iodine deficiency disorders and extensive usage of drugs for treatment of hypothyroidism by people in developing nations. Moreover, counseling of patients about the treatment options for common symptoms such as hypothyroidism is provided at the drug and retail pharmacies, thus providing unique benefit to the segment.
Further, on the basis of Dosage Form, the market is divided into Tablets and Others. The tablet based segment is estimated to hold a major share of the Iodine Deficiency Drug market. This is owing to the factors such as easy availability of tablets, minimum cost, easy to consume, suitable for wide range of population in developed as well as in developing nations.
In the market according to geography, the key regions are North America, Europe, Asia Pacific and Rest of the world. The North America region has the significant contribution in the Iodine Deficiency Drug market due to the rise in the healthcare infrastructure. In addition to this, the increasing awareness about the iodine deficiency will further fuel the expansion of the iodine deficiency market in region.
Moreover, the governments and healthcare organizations worldwide are creating awareness regarding the prominence of iodine in maintaining good health, particularly for pregnant women and children. This awareness is generating demand for iodine supplements and drugs worldwide. Further, iodized salt is a cost-effective and easy way to avoid iodine deficiency. The surging demand for iodized salt is propelling the demand for iodine deficiency drugs, as people who do not consume enough iodized salt may need supplements.
The report of iodine deficiency drugs market consists of profiles of the key vendors- Sanofi, Johnson & Johnson Services, Inc., Apitope Technology (Bristol) Ltd, F. Hoffmann La Roche Ltd, ILDONG PHARMACEUTICAL CO., LTD., Biotex Inc., Novartis AG, Immunovant, Inc., Lupin Pharmaceuticals, Inc., and GlaxoSmithKline plc.
The iodine deficiency is a very common disorder observed across the world which is leading to the numerous serious problems in men and women. As a result, the market for iodine deficiency drug is likely to witness a significant growth in the estimated period.
This study represents the accurate evaluation of the iodine deficiency drugs market size and its share in the parent market
Accurate estimations of future trends and changes in market dynamics are also included in this report.
This report depicts the growth analysis of the iodine deficiency drugs market industry among North America, Asia Pacific, Europe, and rest of the world.
Full analysis of the market's competitive outlook and detailed information of vendors is defined in the study.
Iodine Deficiency Drug Market on the basis of Distribution Channel
Hospital Pharmacies
Drug stores and Retail Pharmacies
Online Providers
Iodine Deficiency Drug Market on the basis of Dosage Form
Tablets
Others
Iodine Deficiency Drug Market on the basis of Geography
North America
Europe
Asia Pacific
Rest of the World
In the market for Distribution Channel, the market is bifurcated into Hospital Pharmacies, Drug stores and Retail Pharmacies and Online Providers. The Drug stores and Retail Pharmacies segment is likely to dominate the Iodine Deficiency Drug market growth. This is due to the surge in demand for iodine deficiency disorders and extensive usage of drugs for treatment of hypothyroidism by people in developing nations. Moreover, counseling of patients about the treatment options for common symptoms such as hypothyroidism is provided at the drug and retail pharmacies, thus providing unique benefit to the segment.
Further, on the basis of Dosage Form, the market is divided into Tablets and Others. The tablet based segment is estimated to hold a major share of the Iodine Deficiency Drug market. This is owing to the factors such as easy availability of tablets, minimum cost, easy to consume, suitable for wide range of population in developed as well as in developing nations.
In the market according to geography, the key regions are North America, Europe, Asia Pacific and Rest of the world. The North America region has the significant contribution in the Iodine Deficiency Drug market due to the rise in the healthcare infrastructure. In addition to this, the increasing awareness about the iodine deficiency will further fuel the expansion of the iodine deficiency market in region.
Moreover, the governments and healthcare organizations worldwide are creating awareness regarding the prominence of iodine in maintaining good health, particularly for pregnant women and children. This awareness is generating demand for iodine supplements and drugs worldwide. Further, iodized salt is a cost-effective and easy way to avoid iodine deficiency. The surging demand for iodized salt is propelling the demand for iodine deficiency drugs, as people who do not consume enough iodized salt may need supplements.
The report of iodine deficiency drugs market consists of profiles of the key vendors- Sanofi, Johnson & Johnson Services, Inc., Apitope Technology (Bristol) Ltd, F. Hoffmann La Roche Ltd, ILDONG PHARMACEUTICAL CO., LTD., Biotex Inc., Novartis AG, Immunovant, Inc., Lupin Pharmaceuticals, Inc., and GlaxoSmithKline plc.
The iodine deficiency is a very common disorder observed across the world which is leading to the numerous serious problems in men and women. As a result, the market for iodine deficiency drug is likely to witness a significant growth in the estimated period.
This study represents the accurate evaluation of the iodine deficiency drugs market size and its share in the parent market
Accurate estimations of future trends and changes in market dynamics are also included in this report.
This report depicts the growth analysis of the iodine deficiency drugs market industry among North America, Asia Pacific, Europe, and rest of the world.
Full analysis of the market's competitive outlook and detailed information of vendors is defined in the study.
1. EXECUTIVE SUMMARY
2. INDUSTRY OUTLOOK
2.1. Industry Overview
2.2. Industry Trends
3. MARKET SNAPSHOT
3.1. Market Definition
3.2. Market Outlook
3.2.1. Porter Five Forces
3.3. Related Markets
4. MARKET CHARACTERISTICS
4.1. Market Overview
4.2. Market Segmentation
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. DRO - Impact Analysis
5. DISTRIBUTION CHANNEL: MARKET SIZE & ANALYSIS
5.1. Overview
5.2. Hospital Pharmacies
5.3. Drug stores and Retail Pharmacies
5.4. Online Providers
6. DOSAGE FORM: MARKET SIZE & ANALYSIS
6.1. Overview
6.2. Tablets
6.3. Others
7. GEOGRAPHY: MARKET SIZE & ANALYSIS
7.1. Overview
7.2. North America
7.3. Europe
7.4. Asia Pacific
7.5. Rest of the World
8. COMPETITIVE LANDSCAPE
8.1. Competitor Comparison Analysis
8.2. Market Developments
8.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships
8.2.2. Product Launches and execution
9. VENDOR PROFILES
9.1. Sanofi
9.1.1. Overview
9.1.2. Financial Overview
9.1.3. Product Offerings
9.1.4. Developments
9.1.5. Business Strategy
9.2. Johnson & Johnson Services, Inc.
9.2.1. Overview
9.2.2. Financial Overview
9.2.3. Product Offerings
9.2.4. Developments
9.2.5. Business Strategy
9.3. Apitope Technology (Bristol) Ltd
9.3.1. Overview
9.3.2. Financial Overview
9.3.3. Product Offerings
9.3.4. Developments
9.3.5. Business Strategy
9.4. F. Hoffmann La Roche Ltd
9.4.1. Overview
9.4.2. Financial Overview
9.4.3. Product Offerings
9.4.4. Developments
9.4.5. Business Strategy
9.5. ILDONG PHARMACEUTICAL CO., LTD.
9.5.1. Overview
9.5.2. Financial Overview
9.5.3. Product Offerings
9.5.4. Developments
9.5.5. Business Strategy
9.6. Biotex Inc.
9.6.1. Overview
9.6.2. Financial Overview
9.6.3. Product Offerings
9.6.4. Developments
9.6.5. Business Strategy
9.7. Novartis AG
9.7.1. Overview
9.7.2. Financial Overview
9.7.3. Product Offerings
9.7.4. Developments
9.7.5. Business Strategy
9.8. Immunovant, Inc.
9.8.1. Overview
9.8.2. Financial Overview
9.8.3. Product Offerings
9.8.4. Developments
9.8.5. Business Strategy
9.9. Lupin Pharmaceuticals, Inc.
9.9.1. Overview
9.9.2. Financial Overview
9.9.3. Product Offerings
9.9.4. Developments
9.9.5. Business Strategy
9.10. GlaxoSmithKline plc
9.10.1. Overview
9.10.2. Financial Overview
9.10.3. Product Offerings
9.10.4. Developments
9.10.5. Business Strategy
10. ANALYST OPINION
11. ANNEXURE
11.1. Report Scope
11.2. Market Definitions
11.3. Research Methodology
11.3.1. Data Collation and In-house Estimation
11.3.2. Market Triangulation
11.3.3. Forecasting
11.4. Report Assumptions
11.5. Declarations
11.6. Stakeholders
11.7. Abbreviations
2. INDUSTRY OUTLOOK
2.1. Industry Overview
2.2. Industry Trends
3. MARKET SNAPSHOT
3.1. Market Definition
3.2. Market Outlook
3.2.1. Porter Five Forces
3.3. Related Markets
4. MARKET CHARACTERISTICS
4.1. Market Overview
4.2. Market Segmentation
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. DRO - Impact Analysis
5. DISTRIBUTION CHANNEL: MARKET SIZE & ANALYSIS
5.1. Overview
5.2. Hospital Pharmacies
5.3. Drug stores and Retail Pharmacies
5.4. Online Providers
6. DOSAGE FORM: MARKET SIZE & ANALYSIS
6.1. Overview
6.2. Tablets
6.3. Others
7. GEOGRAPHY: MARKET SIZE & ANALYSIS
7.1. Overview
7.2. North America
7.3. Europe
7.4. Asia Pacific
7.5. Rest of the World
8. COMPETITIVE LANDSCAPE
8.1. Competitor Comparison Analysis
8.2. Market Developments
8.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships
8.2.2. Product Launches and execution
9. VENDOR PROFILES
9.1. Sanofi
9.1.1. Overview
9.1.2. Financial Overview
9.1.3. Product Offerings
9.1.4. Developments
9.1.5. Business Strategy
9.2. Johnson & Johnson Services, Inc.
9.2.1. Overview
9.2.2. Financial Overview
9.2.3. Product Offerings
9.2.4. Developments
9.2.5. Business Strategy
9.3. Apitope Technology (Bristol) Ltd
9.3.1. Overview
9.3.2. Financial Overview
9.3.3. Product Offerings
9.3.4. Developments
9.3.5. Business Strategy
9.4. F. Hoffmann La Roche Ltd
9.4.1. Overview
9.4.2. Financial Overview
9.4.3. Product Offerings
9.4.4. Developments
9.4.5. Business Strategy
9.5. ILDONG PHARMACEUTICAL CO., LTD.
9.5.1. Overview
9.5.2. Financial Overview
9.5.3. Product Offerings
9.5.4. Developments
9.5.5. Business Strategy
9.6. Biotex Inc.
9.6.1. Overview
9.6.2. Financial Overview
9.6.3. Product Offerings
9.6.4. Developments
9.6.5. Business Strategy
9.7. Novartis AG
9.7.1. Overview
9.7.2. Financial Overview
9.7.3. Product Offerings
9.7.4. Developments
9.7.5. Business Strategy
9.8. Immunovant, Inc.
9.8.1. Overview
9.8.2. Financial Overview
9.8.3. Product Offerings
9.8.4. Developments
9.8.5. Business Strategy
9.9. Lupin Pharmaceuticals, Inc.
9.9.1. Overview
9.9.2. Financial Overview
9.9.3. Product Offerings
9.9.4. Developments
9.9.5. Business Strategy
9.10. GlaxoSmithKline plc
9.10.1. Overview
9.10.2. Financial Overview
9.10.3. Product Offerings
9.10.4. Developments
9.10.5. Business Strategy
10. ANALYST OPINION
11. ANNEXURE
11.1. Report Scope
11.2. Market Definitions
11.3. Research Methodology
11.3.1. Data Collation and In-house Estimation
11.3.2. Market Triangulation
11.3.3. Forecasting
11.4. Report Assumptions
11.5. Declarations
11.6. Stakeholders
11.7. Abbreviations
LIST OF TABLES
TABLE 1. GLOBAL IODINE DEFICIENCY DRUG MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2026 (USD BILLION)
TABLE 2. GLOBAL IODINE DEFICIENCY DRUG MARKET VALUE FOR HOSPITAL PHARMACIES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 3. GLOBAL IODINE DEFICIENCY DRUG MARKET VALUE FOR DRUG STORES AND RETAIL PHARMACIES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 4. GLOBAL IODINE DEFICIENCY DRUG MARKET VALUE FOR ONLINE PROVIDERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 5. GLOBAL IODINE DEFICIENCY DRUG MARKET VALUE, BY DOSAGE FORM, 2021-2027 (USD BILLION)
TABLE 6. GLOBAL IODINE DEFICIENCY DRUG MARKET VALUE FOR TABLETS, 2021-2027 (USD BILLION)
TABLE 7. GLOBAL IODINE DEFICIENCY DRUG MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 8. NORTH AMERICA IODINE DEFICIENCY DRUG MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 9. NORTH AMERICA IODINE DEFICIENCY DRUG MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 10. NORTH AMERICA IODINE DEFICIENCY DRUG MARKET VALUE, BY DOSAGE FORM, 2021-2027 (USD BILLION)
TABLE 11. U.S IODINE DEFICIENCY DRUG MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 12. U.S IODINE DEFICIENCY DRUG MARKET VALUE, BY DOSAGE FORM, 2021-2027 (USD BILLION)
TABLE 13. CANADA IODINE DEFICIENCY DRUG MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 14. CANADA IODINE DEFICIENCY DRUG MARKET VALUE, BY DOSAGE FORM, 2021-2027 (USD BILLION)
TABLE 15. EUROPE IODINE DEFICIENCY DRUG MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 16. EUROPE IODINE DEFICIENCY DRUG MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 17. EUROPE IODINE DEFICIENCY DRUG MARKET VALUE, DOSAGE FORM, 2021-2027 (USD BILLION)
TABLE 18. GERMANY IODINE DEFICIENCY DRUG MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 19. GERMANY IODINE DEFICIENCY DRUG MARKET VALUE, BY DOSAGE FORM, 2021-2027 (USD BILLION)
TABLE 20. U.K IODINE DEFICIENCY DRUG MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 21. U.K IODINE DEFICIENCY DRUG MARKET VALUE, BY DOSAGE FORM, 2021-2027 (USD BILLION)
TABLE 22. FRANCE IODINE DEFICIENCY DRUG MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 23. FRANCE IODINE DEFICIENCY DRUG MARKET VALUE, BY DOSAGE FORM, 2021-2027 (USD BILLION)
TABLE 24. ITALY IODINE DEFICIENCY DRUG MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 25. ITALY IODINE DEFICIENCY DRUG MARKET VALUE, BY DOSAGE FORM, 2021-2027 (USD BILLION)
TABLE 26. SPAIN IODINE DEFICIENCY DRUG MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 27. SPAIN IODINE DEFICIENCY DRUG MARKET VALUE, BY DOSAGE FORM, 2021-2027 (USD BILLION)
TABLE 28. ROE IODINE DEFICIENCY DRUG MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 29. ROE IODINE DEFICIENCY DRUG MARKET VALUE, BY DOSAGE FORM, 2021-2027 (USD BILLION)
TABLE 30. ASIA PACIFC IODINE DEFICIENCY DRUG MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 31. ASIA PACIFC IODINE DEFICIENCY DRUG MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 32. ASIA PACIFC IODINE DEFICIENCY DRUG MARKET VALUE, BY DOSAGE FORM, 2021-2027 (USD BILLION)
TABLE 33. CHINA IODINE DEFICIENCY DRUG MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 34. CHINA IODINE DEFICIENCY DRUG MARKET VALUE, BY DOSAGE FORM, 2021-2027 (USD BILLION)
TABLE 35. INDIA IODINE DEFICIENCY DRUG MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 36. INDIA IODINE DEFICIENCY DRUG MARKET VALUE, BY DOSAGE FORM, 2021-2027 (USD BILLION)
TABLE 37. JAPAN IODINE DEFICIENCY DRUG MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 38. JAPAN IODINE DEFICIENCY DRUG MARKET VALUE, BY DOSAGE FORM, 2021-2027 (USD BILLION)
TABLE 39. REST OF APAC IODINE DEFICIENCY DRUG MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 40. REST OF APAC IODINE DEFICIENCY DRUG MARKET VALUE, BY DOSAGE FORM, 2021-2027 (USD BILLION)
TABLE 41. REST OF WORLD IODINE DEFICIENCY DRUG MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 42. REST OF WORLD IODINE DEFICIENCY DRUG MARKET VALUE, BY DOSAGE FORM, 2021-2027 (USD BILLION)
TABLE 43. SANOFI: FINANCIALS
TABLE 44. SANOFI: PRODUCTS & SERVICES
TABLE 45. SANOFI: RECENT DEVELOPMENTS
TABLE 46. JOHNSON & JOHNSON SERVICES, INC.: FINANCIALS
TABLE 47. JOHNSON & JOHNSON SERVICES, INC.: PRODUCTS & SERVICES
TABLE 48. JOHNSON & JOHNSON SERVICES, INC.: RECENT DEVELOPMENTS
TABLE 49. APITOPE TECHNOLOGY (BRISTOL) LTD: FINANCIALS
TABLE 50. APITOPE TECHNOLOGY (BRISTOL) LTD: PRODUCTS & SERVICES
TABLE 51. APITOPE TECHNOLOGY (BRISTOL) LTD: RECENT DEVELOPMENTS
TABLE 52. F. HOFFMANN LA ROCHE LTD: FINANCIALS
TABLE 53. F. HOFFMANN LA ROCHE LTD: PRODUCTS & SERVICES
TABLE 54. F. HOFFMANN LA ROCHE LTD: RECENT DEVELOPMENTS
TABLE 55. ILDONG PHARMACEUTICAL CO., LTD.: FINANCIALS
TABLE 56. ILDONG PHARMACEUTICAL CO., LTD.: PRODUCTS & SERVICES
TABLE 57. ILDONG PHARMACEUTICAL CO., LTD.: RECENT DEVELOPMENTS
TABLE 58. BIOTEX INC.: FINANCIALS
TABLE 59. BIOTEX INC.: PRODUCTS & SERVICES
TABLE 60. BIOTEX INC.: RECENT DEVELOPMENTS
TABLE 61. NOVARTIS AG: FINANCIALS
TABLE 62. NOVARTIS AG: PRODUCTS & SERVICES
TABLE 63. NOVARTIS AG: RECENT DEVELOPMENTS
TABLE 64. IMMUNOVANT, INC.: FINANCIALS
TABLE 65. IMMUNOVANT, INC.: PRODUCTS & SERVICES
TABLE 66. IMMUNOVANT, INC.: RECENT DEVELOPMENTS
TABLE 67. LUPIN PHARMACEUTICALS, INC.: FINANCIALS
TABLE 68. LUPIN PHARMACEUTICALS, INC.: PRODUCTS & SERVICES
TABLE 69. LUPIN PHARMACEUTICALS, INC.: RECENT DEVELOPMENTS
TABLE 70. GLAXOSMITHKLINE PLC: FINANCIALS
TABLE 71. GLAXOSMITHKLINE PLC: PRODUCTS & SERVICES
TABLE 72. GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS
TABLE 1. GLOBAL IODINE DEFICIENCY DRUG MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2026 (USD BILLION)
TABLE 2. GLOBAL IODINE DEFICIENCY DRUG MARKET VALUE FOR HOSPITAL PHARMACIES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 3. GLOBAL IODINE DEFICIENCY DRUG MARKET VALUE FOR DRUG STORES AND RETAIL PHARMACIES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 4. GLOBAL IODINE DEFICIENCY DRUG MARKET VALUE FOR ONLINE PROVIDERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 5. GLOBAL IODINE DEFICIENCY DRUG MARKET VALUE, BY DOSAGE FORM, 2021-2027 (USD BILLION)
TABLE 6. GLOBAL IODINE DEFICIENCY DRUG MARKET VALUE FOR TABLETS, 2021-2027 (USD BILLION)
TABLE 7. GLOBAL IODINE DEFICIENCY DRUG MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 8. NORTH AMERICA IODINE DEFICIENCY DRUG MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 9. NORTH AMERICA IODINE DEFICIENCY DRUG MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 10. NORTH AMERICA IODINE DEFICIENCY DRUG MARKET VALUE, BY DOSAGE FORM, 2021-2027 (USD BILLION)
TABLE 11. U.S IODINE DEFICIENCY DRUG MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 12. U.S IODINE DEFICIENCY DRUG MARKET VALUE, BY DOSAGE FORM, 2021-2027 (USD BILLION)
TABLE 13. CANADA IODINE DEFICIENCY DRUG MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 14. CANADA IODINE DEFICIENCY DRUG MARKET VALUE, BY DOSAGE FORM, 2021-2027 (USD BILLION)
TABLE 15. EUROPE IODINE DEFICIENCY DRUG MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 16. EUROPE IODINE DEFICIENCY DRUG MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 17. EUROPE IODINE DEFICIENCY DRUG MARKET VALUE, DOSAGE FORM, 2021-2027 (USD BILLION)
TABLE 18. GERMANY IODINE DEFICIENCY DRUG MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 19. GERMANY IODINE DEFICIENCY DRUG MARKET VALUE, BY DOSAGE FORM, 2021-2027 (USD BILLION)
TABLE 20. U.K IODINE DEFICIENCY DRUG MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 21. U.K IODINE DEFICIENCY DRUG MARKET VALUE, BY DOSAGE FORM, 2021-2027 (USD BILLION)
TABLE 22. FRANCE IODINE DEFICIENCY DRUG MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 23. FRANCE IODINE DEFICIENCY DRUG MARKET VALUE, BY DOSAGE FORM, 2021-2027 (USD BILLION)
TABLE 24. ITALY IODINE DEFICIENCY DRUG MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 25. ITALY IODINE DEFICIENCY DRUG MARKET VALUE, BY DOSAGE FORM, 2021-2027 (USD BILLION)
TABLE 26. SPAIN IODINE DEFICIENCY DRUG MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 27. SPAIN IODINE DEFICIENCY DRUG MARKET VALUE, BY DOSAGE FORM, 2021-2027 (USD BILLION)
TABLE 28. ROE IODINE DEFICIENCY DRUG MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 29. ROE IODINE DEFICIENCY DRUG MARKET VALUE, BY DOSAGE FORM, 2021-2027 (USD BILLION)
TABLE 30. ASIA PACIFC IODINE DEFICIENCY DRUG MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 31. ASIA PACIFC IODINE DEFICIENCY DRUG MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 32. ASIA PACIFC IODINE DEFICIENCY DRUG MARKET VALUE, BY DOSAGE FORM, 2021-2027 (USD BILLION)
TABLE 33. CHINA IODINE DEFICIENCY DRUG MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 34. CHINA IODINE DEFICIENCY DRUG MARKET VALUE, BY DOSAGE FORM, 2021-2027 (USD BILLION)
TABLE 35. INDIA IODINE DEFICIENCY DRUG MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 36. INDIA IODINE DEFICIENCY DRUG MARKET VALUE, BY DOSAGE FORM, 2021-2027 (USD BILLION)
TABLE 37. JAPAN IODINE DEFICIENCY DRUG MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 38. JAPAN IODINE DEFICIENCY DRUG MARKET VALUE, BY DOSAGE FORM, 2021-2027 (USD BILLION)
TABLE 39. REST OF APAC IODINE DEFICIENCY DRUG MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 40. REST OF APAC IODINE DEFICIENCY DRUG MARKET VALUE, BY DOSAGE FORM, 2021-2027 (USD BILLION)
TABLE 41. REST OF WORLD IODINE DEFICIENCY DRUG MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 42. REST OF WORLD IODINE DEFICIENCY DRUG MARKET VALUE, BY DOSAGE FORM, 2021-2027 (USD BILLION)
TABLE 43. SANOFI: FINANCIALS
TABLE 44. SANOFI: PRODUCTS & SERVICES
TABLE 45. SANOFI: RECENT DEVELOPMENTS
TABLE 46. JOHNSON & JOHNSON SERVICES, INC.: FINANCIALS
TABLE 47. JOHNSON & JOHNSON SERVICES, INC.: PRODUCTS & SERVICES
TABLE 48. JOHNSON & JOHNSON SERVICES, INC.: RECENT DEVELOPMENTS
TABLE 49. APITOPE TECHNOLOGY (BRISTOL) LTD: FINANCIALS
TABLE 50. APITOPE TECHNOLOGY (BRISTOL) LTD: PRODUCTS & SERVICES
TABLE 51. APITOPE TECHNOLOGY (BRISTOL) LTD: RECENT DEVELOPMENTS
TABLE 52. F. HOFFMANN LA ROCHE LTD: FINANCIALS
TABLE 53. F. HOFFMANN LA ROCHE LTD: PRODUCTS & SERVICES
TABLE 54. F. HOFFMANN LA ROCHE LTD: RECENT DEVELOPMENTS
TABLE 55. ILDONG PHARMACEUTICAL CO., LTD.: FINANCIALS
TABLE 56. ILDONG PHARMACEUTICAL CO., LTD.: PRODUCTS & SERVICES
TABLE 57. ILDONG PHARMACEUTICAL CO., LTD.: RECENT DEVELOPMENTS
TABLE 58. BIOTEX INC.: FINANCIALS
TABLE 59. BIOTEX INC.: PRODUCTS & SERVICES
TABLE 60. BIOTEX INC.: RECENT DEVELOPMENTS
TABLE 61. NOVARTIS AG: FINANCIALS
TABLE 62. NOVARTIS AG: PRODUCTS & SERVICES
TABLE 63. NOVARTIS AG: RECENT DEVELOPMENTS
TABLE 64. IMMUNOVANT, INC.: FINANCIALS
TABLE 65. IMMUNOVANT, INC.: PRODUCTS & SERVICES
TABLE 66. IMMUNOVANT, INC.: RECENT DEVELOPMENTS
TABLE 67. LUPIN PHARMACEUTICALS, INC.: FINANCIALS
TABLE 68. LUPIN PHARMACEUTICALS, INC.: PRODUCTS & SERVICES
TABLE 69. LUPIN PHARMACEUTICALS, INC.: RECENT DEVELOPMENTS
TABLE 70. GLAXOSMITHKLINE PLC: FINANCIALS
TABLE 71. GLAXOSMITHKLINE PLC: PRODUCTS & SERVICES
TABLE 72. GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS
